2022 Annual Meeting | Industry Therapeutic Update from argenx: Innovation in Anti-AChR Antibody Positive gMG Treatment for Adults: Clinical Data of VYVGART™ (efgartigimod alfa-fcab) in the Pivotal ADAPT Trial

Date Tuesday 04/05/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives Join us for dinner as we discuss the phase 3 pivotal trial data for the recently approved VYVGARTTM (efgartigimod alfa-fcab). VYVGART offers a novel mechanism of action for treating anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis (gMG) in adults. gMG is a rare but debilitating disease, whereby pathogenic immunoglobulin G (IgG) autoantibodies cause failure of signal transmission at the neuromuscular junction. The neonatal Fc receptor (FcRn) is a molecule that recycles IgG antibodies, including pathogenic autoantibodies, rescuing them from lysosomal degradation and perpetuating the underlying pathophysiology behind gMG. VYVGART is a human IgG1-derived Fc fragment that blocks FcRn and prevents IgG recycling, resulting in a reduction of circulating IgG, including levels of pathogenic autoantibodies that impair neuromuscular transmission in adult patients with gMG who are anti-AChR antibody positive. Get your questions answered by our distinguished panelists, all directly involved in the pivotal trial.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN.
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available 0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from argenx: Innovation in Anti-AChR Antibody Positive gMG Treatment for Adults: Clinical Data of VYVGART™ (efgartigimod alfa-fcab) in the Pivotal ADAPT Trial

Faculty Disclosures
James F. Howard, Jr., MD, FAAN	Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for arenx . Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Pharmaceuticals. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ra Pharma (now UCB Biosciences). Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi US. Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Academic CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PeerView CME. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Platform Q CME. Dr. Howard has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Zai Laboratories. Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Medscape CME. Dr. Howard has stock in General Electric dividends. Dr. Howard has stock in Johnson & Johnson dividends. Dr. Howard has stock in Pfizer dividends. An immediate family member of Dr. Howard has stock in GlaxoSmithKline dividends. An immediate family member of Dr. Howard has stock in GE Healthcare dividends. The institution of Dr. Howard has received research support from Alexion Pharmaceuticals. The institution of Dr. Howard has received research support from argenx . The institution of Dr. Howard has received research support from UCB Biosciences. The institution of Dr. Howard has received research support from NIH. The institution of Dr. Howard has received research support from Centers for Disease Control/Research Triangle Institute. The institution of Dr. Howard has received research support from Duke University (DCRI). The institution of Dr. Howard has received research support from Cartestian Therapeutics. Dr. Howard has a non-compensated relationship as a Scientific Advisiory Board member, Committee member with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities. Dr. Howard has a non-compensated relationship as a Committee member with American Assoc Neuromuscular and Electrodiagnostic Medicine that is relevant to AAN interests or activities.
Gil I. Wolfe, MD, FAAN	Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB/Ra. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Grifols. The institution of Dr. Wolfe has received research support from UCB/Ra. The institution of Dr. Wolfe has received research support from ArgenX. Dr. Wolfe has received personal compensation in the range of $0-$499 for serving as a Advisor with FDA Advisory Panel for Cellular, Tissue and Genetic Therapies.
	No disclosure on file